USPTO Examiner HUTTER GILLIAN A - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18956941COMPOSITIONS AND METHODS FOR TREATING CANCERNovember 2024June 2025Allow611NoNo
187832312,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1July 2024February 2025Allow710NoNo
18710113FERROPTOSIS INHIBITOR AND USE THEREFORMay 2024February 2025Allow911YesNo
18611561NANOMATERIALS COMPRISING TRIOLSMarch 2024December 2024Allow911NoNo
18606722SMALL MOLECULE COMPOUNDS HAVING NAPHTHYLAMINE STRUCTURE AND APPLICATION THEREOFMarch 2024September 2024Allow711NoNo
184431364-THIAZOLIDINONE DERIVATIVES AS EGFR INHIBITORS FOR ANTI-TUMOR ACTIVITYFebruary 2024July 2024Allow501NoNo
18405638COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITORJanuary 2024August 2024Allow711NoNo
18393644PYRIMIDO[1',6':1,5]PYRAZOLO[4,3-B][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSDecember 2023August 2024Allow810NoNo
18542368PYRIDO[4',3':4,5]PYRROLO[2,3-C][2,7]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSDecember 2023August 2024Allow801NoNo
18115020TERPENE-ENRICHED CANNABINOID COMPOSITION AND METHOD OF TREATMENTFebruary 2023December 2023Allow911YesNo
18154752COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USEJanuary 2023July 2024Abandon1811NoNo
18050269COMPOSITIONS AND METHODS FOR TREATING CANCEROctober 2022April 2023Allow610YesNo
18048478SYNERGISTIC COMPOSITION FOR VEISALGIA PREVENTIONOctober 2022December 2023Abandon1310NoNo
17959751DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAMEOctober 2022December 2024Abandon2711NoNo
17934009METHODS OF TREATING FIBROTIC PATHOLOGIESSeptember 2022June 2024Abandon2111NoNo
17864095COMPOSITIONS AND METHODS USING CANNABINOID COMPOUNDS FOR REGULATING GASTRIC ACID SECRETION TO TREAT GASTROESOPHAGEAL REFLUX DISEASE AND RELATED CONDITIONSJuly 2022March 2024Abandon2001NoNo
17851954NEUROLYTIC AGENTS AND METHODS OF USING AND IDENTIFYING SAMEJune 2022April 2025Allow3321YesNo
17845251INTOXICATION-REDUCING SUPPLEMENTAL MIXTUREJune 2022December 2024Abandon3021NoNo
17715276ENDOCANNABINOID SYSTEM-TARGETING PRODRUGS AND THERAPEUTIC USES THEREOFApril 2022October 2023Abandon1801NoNo
17711105COMPOSITIONS CONTAINING ANDROGEN RECEPTOR ANTAGONISTSApril 2022May 2024Abandon2511NoNo
17680995COMBINATION THERAPIES FOR THE TREATMENT OF CANCERFebruary 2022August 2024Allow3011NoNo
17668316CONJOINT THERAPY FOR TREATING SEIZURE DISORDERSFebruary 2022May 2024Abandon2711NoNo
17666197pH STABLE UREA COMPOSITION AND USE THEREOFFebruary 2022August 2024Abandon3021NoNo
17665493SYNERGISTIC COMPOSITION FOR VEISALGIA PREVENTIONFebruary 2022September 2023Abandon1910YesNo
17523002KP372-1-INDUCED DNA DAMAGE AS A CHEMOTHERAPEUTIC APPROACH TO TREAT CANCERNovember 2021June 2024Allow3121NoNo
17521004COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITYNovember 2021March 2024Allow2921YesNo
17519771Composition for increasing skin thicknessNovember 2021July 2023Abandon2001NoNo
17518952COMPOSITION AND METHOD FOR TREATMENT OF DIABETESNovember 2021March 2024Abandon2820NoNo
17496921BACE1 INHIBITORY LIGAND MOLECULES AGAINST AMYLOID BETA-INDUCED SYNAPTIC AND MITOCHONDRIAL TOXICITIESOctober 2021May 2024Allow3121NoNo
17489255FULL SPECTRUM HEMP OIL COMPOSITIONSSeptember 2021September 2024Allow3521YesNo
17487430ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVESeptember 2021July 2023Abandon2110NoNo
17437375FGFR4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFSeptember 2021May 2025Abandon4501NoNo
17464233BRONCHODILATORS FOR TREATING OBSTRUCTIVE LUNG DISEASESeptember 2021December 2024Allow3940YesNo
17300593Pharmaceutical composition to destabilize abnormal methylation enzymes and use thereofAugust 2021June 2023Abandon2101NoNo
17432279COMPOSITIONS PROVIDING ENHANCED ANTIBACTERIAL ACTIVITY AGAINST GRAM-POSITIVE BACTERIA AND USE THEREOFAugust 2021May 2025Abandon4501NoNo
17429707INJECTABLE CLORSULON COMPOSITIONS, METHODS AND USES THEREOFAugust 2021February 2025Abandon4210NoNo
17385748BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDSJuly 2021March 2024Allow3221YesNo
17383930COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOFJuly 2021October 2024Allow3931YesNo
17310032COMBINATION OF SELECTIVE ALPHA-ADRENERGIC RECEPTOR AGONIST OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOFJuly 2021March 2024Abandon3211NoNo
17371941CANNABIS EXTRACTS AND USES THEREOFJuly 2021December 2023Abandon2911NoNo
17419915Topical Formulation for Use in AlopeciaJune 2021January 2024Allow3111YesNo
17417727CANCER TREATMENT PHARMACEUTICAL COMPOSITION CONTAINING CDK INHIBITORJune 2021December 2024Abandon4201NoNo
17415813NOTCH INHIBITORS FOR THE TREATMENT OF VASCULAR MALFORMATIONSJune 2021June 2025Abandon4711NoNo
17414672N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of DiseaseJune 2021December 2024Abandon4201NoNo
17413689INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTSJune 2021May 2024Allow3511YesNo
17296098BENZHYDRYLATED AROMATIC SURFACTANTSMay 2021March 2024Abandon3401NoNo
17319500COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2May 2021March 2025Abandon4631NoNo
17290417NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)April 2021September 2024Abandon4001NoNo
17290354NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)April 2021September 2024Abandon4001NoNo
17244094BRIMONIDINE COMBINATIONS AND USES THEREOFApril 2021December 2024Abandon4421NoNo
17284011The use of a H3R inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (PD)April 2021January 2023Abandon2110NoNo
17283904TREATMENT OF PRURITUS WITH P2X3 MODULATORSApril 2021August 2024Abandon4011NoNo
17220307ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCERApril 2021June 2025Allow5031NoNo
17280929METHODS AND COMPOSITIONS FOR REDUCING SERUM URIC ACIDMarch 2021December 2023Abandon3201NoNo
17212737COMPOSITIONS AND METHODS FOR TREATING CANCERMarch 2021October 2022Allow1911NoNo
172786252'-HALOGENATED-4'-THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOFMarch 2021February 2025Abandon4721NoNo
17197395SLEEP AID AND RELATED METHODSMarch 2021December 2023Abandon3321NoNo
17274175Treatment of inflammatory bowel disease and its extra intestinal manifestationsMarch 2021March 2025Abandon4841NoNo
17271009FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)February 2021April 2025Allow5021NoNo
17270588SELENOPHENOCHROMENE HYDROXAMIC ACIDS, PREPARATION AND USE AS ANGIOGENESIS INHIBITORSFebruary 2021April 2024Allow3701YesNo
17173841ADMINISTRATION OF ANTIPSYCHOTICSFebruary 2021June 2024Allow4041YesNo
17266751COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOADFebruary 2021May 2025Allow5141YesNo
17266960COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USEFebruary 2021April 2023Abandon2611NoNo
17265036COMPOSITIONS COMPRISING PROPOFOL, KETAMINE, AND ANALGESIC, AND METHODS OF USEFebruary 2021December 2022Abandon2301NoNo
17260193INHIBITORS OF HISTONE DEACETYLASEJanuary 2021September 2024Abandon4411NoNo
17146013USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASEJanuary 2021December 2023Abandon3521NoNo
17258626COMPOUNDS FOR MYC INHIBITIONJanuary 2021November 2022Allow2221NoNo
17258402COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITISJanuary 2021April 2023Allow2711NoNo
17258054COMBINATION THERAPY WITH MEK INHIBITOR AND CDK4/6 INHIBITOR TO TREAT PANCREATIC CANCERJanuary 2021December 2022Allow2311NoNo
17255662PHARMACEUTICAL COMBINATION FOR USE IN AGE-RELATED AND/OR DEGENERATIVE DISEASESDecember 2020April 2024Allow4031NoNo
17254323COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASEDecember 2020June 2023Abandon2921NoNo
17126380SYNERGISTIC ANTI-INFLAMMATORY COMPOSITIONSDecember 2020July 2023Allow3121NoNo
17253545METHOD OF TREATING EPILEPSY OR EPILEPTIC ENCEPHALOPATHY WITH FENFLURAMINE IN PATIENTS WITHOUT PULMONARY HYPERTENSIONDecember 2020December 2022Abandon2410NoNo
17120681DEUTERATED CFTR POTENTIATORSDecember 2020February 2025Abandon5020NoNo
17119661METHODS OF TREATING CANCERDecember 2020February 2024Allow3820NoYes
16973514AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORSDecember 2020November 2024Abandon4811NoNo
17112887MASP-2 INHIBITORS AND METHODS OF USEDecember 2020January 2023Allow2521NoNo
16972288TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION FOR GLIOMADecember 2020March 2023Abandon2820YesNo
17059754Novel Biphenyl Derivative Compound and Use ThereofNovember 2020November 2023Allow3611YesNo
17105087OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONNovember 2020May 2025Abandon5421NoNo
17058187ION CHANNEL MODULATORSNovember 2020August 2023Allow3300NoNo
17057247Methods of Treating Renal Disease Associated With Chronic Kidney Disease Such as Alport SyndromeNovember 2020July 2024Abandon4430NoNo
15733732Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combinationOctober 2020July 2022Allow2110YesNo
17021438COMPOUNDS USEFUL AS NEAR-INFRARED FLUORESCENT PROBES SELECTIVELY BINDING TO TAU AGGREGATES AND METHOD OF PREPARING THE SAMESeptember 2020March 2024Allow4241NoNo
16977318GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASESSeptember 2020May 2024Abandon4521NoNo
16975865EPILEPSY TREATMENT AGENTAugust 2020February 2023Allow3020NoNo
16975439HEMATOPOIESIS-ENHANCING AGENTAugust 2020October 2022Allow2611NoNo
16970879Targeting Lipid Metabolism and Free Fatty Acid (FFA) Oxidation to Treat Diseases Mediated by Resident Memory T Cells (TRM)August 2020November 2022Abandon2711NoNo
16992674DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAMEAugust 2020September 2022Allow2511YesNo
16967401Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use ThereofAugust 2020April 2025Allow5641NoNo
16965122METHODS OF TREATING FIBROTIC PATHOLOGIESJuly 2020October 2022Abandon2711NoNo
16963107Langerin+ Cell TargetingJuly 2020October 2024Allow5111YesNo
16961784ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTSJuly 2020October 2022Allow2711NoNo
16961201PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONSJuly 2020January 2023Abandon3111NoNo
16960226COMPOSITION CONTAINING SUMO INHIBITOR AND APPLICATIONJuly 2020October 2022Allow2711NoNo
16913834COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERSJune 2020December 2022Allow3011NoNo
16898889PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTSJune 2020August 2022Allow2611YesNo
16897272USE OF HYDROXYTYROSOL ACETATE IN IMPROVING FUNCTION OF AORTIC ENDOTHELIAL CELLJune 2020January 2023Abandon3111NoNo
16888778Treating Cancer with Drug CombinationsMay 2020February 2023Abandon3311NoNo
16762000SULFONAMIDE CARBOXAMIDE COMPOUNDSMay 2020September 2024Allow5341NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUTTER, GILLIAN A.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HUTTER, GILLIAN A - Prosecution Strategy Guide

Executive Summary

Examiner HUTTER, GILLIAN A works in Art Unit 1625 and has examined 104 patent applications in our dataset. With an allowance rate of 47.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner HUTTER, GILLIAN A's allowance rate of 47.1% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HUTTER, GILLIAN A receive 1.43 office actions before reaching final disposition. This places the examiner in the 32% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HUTTER, GILLIAN A is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +60.3% benefit to allowance rate for applications examined by HUTTER, GILLIAN A. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 36.4% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 47.1% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.